Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms. Described herein are solid oral dosage forms containing Compound (1) or a pharmaceutically acceptable salt thereof (Formula 1), wherein Compound (1) is in the amorphous state. Also described are solid oral dosage forms comprising a composition of Compound (1) in the amorphous state and one or more pharmaceutically acceptable excipients. Compound (1) is a specific inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. Thus, also described herein are methods for using the described solid oral dosage forms in the treatment of HCV infection. Also described are processes for the manufacture of the solid oral dosage forms. A method includes receiving data representing measurements acquired by seismic sensors in response to energy that is produced by shots of a seismic source. The energy that is produced by the seismic source for each shot includes a plurality of discrete frequencies of discrete frequency bands that are within a frequency range of interest and are separated by at least one excluded frequency or frequency band. The data may be processed to determine at least one characteristic of a geologic structure.En la presente se describen formas de dosificación oral sólida que contienen el compuesto (1) o una sal de este aceptable desde el punto de vista farmacéutico: (ver Fórmula) en donde el compuesto (1) está en estado amorfo. Tambi
